Nurix Initiates DAYBreak⢠Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia
Provided By GlobeNewswire
Last update: Oct 22, 2025
600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL)
Read more at globenewswire.com
